Identification and preliminary structure–activity relationship of brain‐penetrant quinoxaline‐based compounds with in vitro anti‐glioblastoma activity

A central nervous system (CNS)‐oriented compound collection was screened to find hit compounds for human glioblastoma T98G cell growth inhibition. A series of quinoxaline‐based derivatives were identified as hit compounds having one‐ to two‐digit micromolar GI50 values. Anti‐glioblastoma activity wa...

Full description

Saved in:

Bibliographic Details
Published in:	Bulletin of the Korean Chemical Society Vol. 44; no. 11; pp. 932 - 938
Main Authors:	Ahn, Seohyeon, Kim, Eun Hye, Lee, Chaemi, Nam, Yoon Chae, Lee, Joo‐Youn, Song, Jin Sook, Kim, Seong Hwan, Jeon, Moon‐Kook
Format:	Journal Article
Language:	English
Published:	Weinheim Wiley‐VCH Verlag GmbH & Co. KGaA 01-11-2023 대한화학회
Subjects:	brain penetration central nervous system glioblastoma growth inhibition quinoxaline 화학
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A central nervous system (CNS)‐oriented compound collection was screened to find hit compounds for human glioblastoma T98G cell growth inhibition. A series of quinoxaline‐based derivatives were identified as hit compounds having one‐ to two‐digit micromolar GI50 values. Anti‐glioblastoma activity was improved in structure–activity relationship studies varying the substituents on the quinoxaline ring system, resulting in the discovery of four compounds exhibiting sub‐micromolar GI50 values. The potentials of the four compounds to induce apoptosis were confirmed by annexin V staining assay. The development potential of the four compounds as CNS drug leads was evaluated by in vitro MDR‐MDCK cell permeability and in vivo brain disposition in mice. The mouse pharmacokinetic and kinome profiling studies for compound 10g, which showed high brain‐penetrating ability, revealed that the compound is orally bioavailable and inhibits the kinase activities of anaplastic lymphoma kinase (ALK) and Erb‐B2 receptor tyrosine kinase (ERBB3). We identified four quinoxaline‐based compounds exhibiting sub‐micromolar GI50 values by screening a CNS‐oriented compound collection for glioblastoma T98G cell growth inhibition and subsequent structure–activity relationship studies. The promising features of the four compounds as CNS drug leads were shown by the mouse brain/plasma ratios.
Bibliography:	Seohyeon Ahn and Eun Hye Kim contributed equally to this article.
ISSN:	1229-5949 0253-2964 1229-5949
DOI:	10.1002/bkcs.12773